$OCUL this is our much anticipated news from the Oct 30th meeting with the FDA re: OTX-TP "...and pausing further activities in connection with its OTX-TP program for the treatment of primary open-angle glaucoma or ocular hypertension, other than an ongoing open-label safety extension study, while the Company seeks to identify a collaborative partner for the program."
  • 2
  • 1